The inhibition of BRD2, BRD3, and BRD4 shortens signaling between super-enhancer regions and oncogene target promoters, resulting in cell-specific inhibition of oncogene expression and ultimately cancer cell death. The gene discussed is BRD2; the disease is cancer.